Literature DB >> 7439053

[Clinical results with a new intravenous immunoglobulin preparation (author's transl)].

W Hansi, G Kratzsch, H Heimpel.   

Abstract

A new immunoglobulin preparation (Sandoglobulin) was administered to 20 patients, a total of 49 infusions at a dose averaging 12.6 gamma-globulin per infusion. Twelve patients had congenital or acquired immunoglobulin deficiency, in come of them very severe. A In-vivo recovery, on the basis of an estimated plasma volume, averaged 85% of expected values. Half-life on repeat substitutions was over 20 days. There were no severe side-effects or changes in important biochemical values. In one woman with an antibody deficiency syndrome fever regularly developed after several infusions, but it always fell to normal spontaneously after several hours. In two women followed for some time, both with severe antibody-deficiency syndrome, there was a definite decrease in severity and frequency of pulmonary infections.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439053     DOI: 10.1055/s-2008-1070935

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

2.  Some side effects of intravenous 7S-immunoglobulins are due to immune complexes and can be prevented by 5S-immunoglobulin given prior to 7S treatment.

Authors:  G P Tilz
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

3.  [Tolerance of a new intravenously applied immunoglobulin preparation and its effect on serum globulin levels].

Authors:  W Hansi; H Heimpel; S Barandun; O Lutz
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.